Is tapering and stopping of tofacitinib possible among pediatric and adolescent alopecia areata patients?

Alopecia areata (AA) is an autoimmune condition characterized by non-scarring patchy alopecia.e condition affects all age groups, and an early age of onset (<12 years) is associated with an increased risk of developing chronic alopecia areata (CAA) and alopecia Totalis/universalis (AT/ AU), which may lead to a poor response to therapy. [1]Among all patients of AA, almost half experience disease onset within the first two decades of life, making it the most common cause of alopecia in children. [2]e various available treatment options for moderate to severe AA include topical immunotherapy/ contact irritants, systemic steroids, and steroid-sparing agents like cyclosporine, azathioprine, methotrexate, and the Janus kinase inhibitors.